Involvement of B cells, immunoglobulins, and syk in the pathogenesis of abdominal aortic aneurysm

Journal of the American Heart Association

Volumn 7, Issue 6, 2018, Pages

  Furusho, Aya ^a   Aoki, Hiroki ^b   Ohno Urabe, Satoko ^a   Nishihara, Michihide ^a   Hirakata, Saki ^a   Nishida, Norifumi ^a   Ito, Sohei ^a   Hayashi, Makiko ^a   Imaizumi, Tsutomu ^c   Hiromatsu, Shinichi ^a   Akashi, Hidetoshi ^a   Tanaka, Hiroyuki ^a   Fukumoto, Yoshihiro ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KURUME UNIVERSITY   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Abdominal aortic aneurysm; B cells; Immune system; Immunoglobulins; Inflammation; Syk

Indexed keywords

GELATINASE B; IMMUNOGLOBULIN; INTERLEUKIN 6; PROTEIN KINASE SYK; CALCIUM CHLORIDE; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MMP9 PROTEIN, HUMAN; MMP9 PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; SYK PROTEIN, HUMAN; SYK PROTEIN, MOUSE;

ABDOMINAL AORTIC ANEURYSM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN DEPOSITION; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TISSUE CULTURE; ABDOMINAL AORTA; ANIMAL; B LYMPHOCYTE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENETICS; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; TISSUE CULTURE TECHNIQUE;

ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; B-LYMPHOCYTES; CALCIUM CHLORIDE; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN-6; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MICE, INBRED C57BL; MICE, KNOCKOUT; PROTEIN KINASE INHIBITORS; SYK KINASE; TISSUE CULTURE TECHNIQUES;

EID: 85043693560     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.117.007750     Document Type: Article

References (41)

1. Cronenwett JL, Johnston KW. Vascular Surgery. Philadelphia: Elsevier Health Sciences; 2014
2. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL, Hiratzka LF, Murphy WR, Olin JW, Puschett JB, Rosenfield KA, Sacks D, Stanley JC, Taylor LM Jr, White CJ, White J, White RA, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Hunt SA, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113:e463-e654
3. EVAR Trial Participants. Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial. Lancet. 2005;365:2179-2186
4. EVAR Trial Participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): randomised controlled trial. Lancet. 2005;365:2187-2192
5. Bergoeing MP, Thompson RW, Curci JA. Pharmacological targets in the treatment of abdominal aortic aneurysms. Expert Opin Ther Targets. 2006;10:547-559
6. Senemaud J, Caligiuri G, Etienne H, Delbosc S, Michel JB, Coscas R. Translational relevance and recent advances of animal models of abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol. 2017;37:401-410
7. Emeto TI, Seto SW, Golledge J. Targets for medical therapy to limit abdominal aortic aneurysm progression. Curr Drug Targets. 2014;15:860-873
8. Aoki H, Yoshimura K, Matsuzaki M. Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy. J Mol Med. 2007;85:1077-1088
9. Guessous I, Periard D, Lorenzetti D, Cornuz J, Ghali WA. The efficacy of pharmacotherapy for decreasing the expansion rate of abdominal aortic aneurysms: a systematic review and meta-analysis. PLoS One. 2008;3: e1895
10. Ocana E, Bohorquez JC, Perez-Requena J, Brieva JA, Rodriguez C. Characterisation of T and B lymphocytes infiltrating abdominal aortic aneurysms. Atherosclerosis. 2003;170:39-48
11. Zhang L, Wang Y. B lymphocytes in abdominal aortic aneurysms. Atherosclerosis. 2015;242:311-317
12. Shimizu K, Mitchell RN, Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2006;26:987-994
13. Zhou HF, Yan H, Bertram P, Hu Y, Springer LE, Thompson RW, Curci JA, Hourcade DE, Pham CT. Fibrinogen-specific antibody induces abdominal aortic aneurysm in mice through complement lectin pathway activation. Proc Natl Acad Sci USA. 2013;110:E4335-E4344
14. Zhou HF, Yan H, Stover CM, Fernandez TM, Rodriguez de Cordoba S, Song WC, Wu X, Thompson RW, Schwaeble WJ, Atkinson JP, Hourcade DE, Pham CT. Antibody directs properdin-dependent activation of the complement alternative pathway in a mouse model of abdominal aortic aneurysm. Proc Natl Acad Sci USA. 2012;109:E415-E422
15. Schaheen B, Downs EA, Serbulea V, Almenara CC, Spinosa M, Su G, Zhao Y, Srikakulapu P, Butts C, McNamara CA, Leitinger N, Upchurch GR Jr, Meher AK, Ailawadi G. B-cell depletion promotes aortic infiltration of immunosuppressive cells and is protective of experimental aortic aneurysm. Arterioscler Thromb Vasc Biol. 2016;36:2191-2202
16. Meher AK, Johnston WF, Lu G, Pope NH, Bhamidipati CM, Harmon DB, Su G, Zhao Y, McNamara CA, Upchurch GR Jr, Ailawadi G. B2 cells suppress experimental abdominal aortic aneurysms. Am J Pathol. 2014;184:3130-3141
17. Wang Y, Krishna S, Golledge J. The calcium chloride-induced rodent model of abdominal aortic aneurysm. Atherosclerosis. 2013;226:29-39
18. Deng GM, Kyttaris VC, Tsokos GC. Targeting Syk in autoimmune rheumatic diseases. Front Immunol. 2016;7:78
19. Kurosaki T, Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunol Rev. 2009;228:132-148
20. Daeron M. Fc receptor biology. Annu Rev Immunol. 1997;15:203-234
21. Geahlen RL. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol Sci. 2014;35:414-422
22. Furusho A, Aoki H, Ohno-Urabe S, Nishihara M, Hirakata S, Nishida N, Ito S, Hayashi M, Imaizumi T, Hiromatsu S, Akashi H, Tanaka N, Fukumoto Y. Involvement of B cells, immunoglobulins, and Syk in the pathogenesis of abdominal aortic aneurysm. 2018. Gene Expression Omnibus, NCBI. GSE109640
23. Nishihara M, Aoki H, Ohno S, Furusho A, Hirakata S, Nishida N, Ito S, Hayashi M, Imaizumi T, Fukumoto Y. The role of IL-6 in pathogenesis of abdominal aortic aneurysm in mice. PLoS One. 2017;12:e0185923
24. Colonna L, Catalano G, Chew C, D'Agati V, Thomas JW, Wong FS, Schmitz J, Masuda ES, Reizis B, Tarakhovsky A, Clynes R. Therapeutic targeting of Syk in autoimmune diabetes. J Immunol. 2010;185:1532-1543
25. Kitamura D, Roes J, Kuhn R, Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin l chain gene. Nature. 1991;350:423-426
26. Yoshimura K, Aoki H, Ikeda Y, Fujii K, Akiyama N, Furutani A, Hoshii Y, Tanaka N, Ricci R, Ishihara T, Esato K, Hamano K, Matsuzaki M. Regression of abdominal aortic aneurysm by inhibition of c-Jun N-terminal kinase. Nat Med. 2005;11:1330-1338
27. da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44-57
28. Tsubata T, Wienands J. B cell signaling. Introduction. Int Rev Immunol. 2001;20:675-678
29. Yi YS, Son YJ, Ryou C, Sung GH, Kim JH, Cho JY. Functional roles of Syk in macrophage-mediated inflammatory responses. Mediators Inflamm. 2014;2014:270302
30. Uchida HA, Kristo F, Rateri DL, Lu H, Charnigo R, Cassis LA, Daugherty A. Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Atherosclerosis. 2010;211:399-403
31. Ait-Oufella H, Wang Y, Herbin O, Bourcier S, Potteaux S, Joffre J, Loyer X, Ponnuswamy P, Esposito B, Dalloz M, Laurans L, Tedgui A, Mallat Z. Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. Arterioscler Thromb Vasc Biol. 2013;33:2374-2379
32. Meng X, Yang J, Zhang K, An G, Kong J, Jiang F, Zhang Y, Zhang C. Regulatory T cells prevent angiotensin II-induced abdominal aortic aneurysm in apolipoprotein E knockout mice. Hypertension. 2014;64:875-882
33. Yodoi K, Yamashita T, Sasaki N, Kasahara K, Emoto T, Matsumoto T, Kita T, Sasaki Y, Mizoguchi T, Sparwasser T, Hirata K. Foxp3+ regulatory T cells play a protective role in angiotensin II-induced aortic aneurysm formation in mice. Hypertension. 2015;65:889-895
34. Denyer J, Patel V. Syk kinase inhibitors in allergic diseases. Drug News Perspect. 2009;22:146-150
35. Lucas MC, Tan SL. Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations? Future Med Chem. 2014;6:1811-1827
36. Navara CS. The spleen tyrosine kinase (Syk) in human disease, implications for design of tyrosine kinase inhibitor based therapy. Curr Pharm Des. 2004;10:1739-1744
37. Raffort J, Lareyre F, Clement M, Hassen-Khodja R, Chinetti G, Mallat Z. Monocytes and macrophages in abdominal aortic aneurysm. Nat Rev Cardiol. 2017;14:457-471
38. Arnaoutoglou E, Kouvelos G, Milionis H, Mavridis A, Kolaitis N, Papa N, Papadopoulos G, Matsagkas M. Post-implantation syndrome following endovascular abdominal aortic aneurysm repair: preliminary data. Interact Cardiovasc Thorac Surg. 2011;12:609-614
39. Ng E, Morris DR, Golledge J. The association between plasma matrix metalloproteinase-9 concentration and endoleak after endovascular aortic aneurysm repair: a meta-analysis. Atherosclerosis. 2015;242:535-542
40. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of abdominal aortic aneurysm progression. Part 2: inflammation. Nat Rev Cardiol. 2009;6:543-552
41. Hellenthal FA, Buurman WA, Wodzig WK, Schurink GW. Biomarkers of AAA progression. Part 1: extracellular matrix degeneration. Nat Rev Cardiol. 2009;6:464-474